Marinus Pharmaceuticals Inc. (MRNS) NASDAQ
$9.04 0.19 (2.15%)
Market Cap: $493.97M
As of 03/28/24 04:00 PM EDT. Market closed.
Marinus Pharmaceuticals Inc. (MRNS)
NASDAQ
$9.04
0.19 (2.15%)
Market Cap: $493.97M
As of 03/28/24 04:00 PM EDT. Market closed.
marinus pharmaceuticals is a clinical stage biopharmaceutical company dedicated to positively impacting the well-being of patients who suffer from epilepsy and neuropsychiatric disorders. the company is in the midst of developing and commercializing ganaxolone which will treat adults and children with epileptic seizures and women with postpartum depression. on june 29, 2017, the company announced ... read more
marinus pharmaceuticals is a clinical stage biopharmaceutical company dedicated to positively impacting the well-being of patients who suffer from epilepsy and neuropsychiatric disorders. the company is in the midst of developing and commercializing ganaxolone which will treat adults and children with epileptic seizures and women with postpartum depression. on june 29, 2017, the company announced that the u.s. food and drug administration (fda) granted orphan drug designation to ganaxolone for the treatment of cdkl5 disorder. cdkl5 disorder is a severe, rare genetic disorder that affects children at an early age and causes difficult-to-control seizures and neuro-developmental impairment. currently, there are no approved therapies for children with cdkl5 disorder. orphan drug designation is granted by the fda office of orphan products development to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the u.s. the designation provides read less
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
Braunstein Scott | CHAIRMAN AND CEO | Mar 27, 2024 | Option Exercise | $4.28 | 50,000 | 214,000 | 273,512 | Mar 27, 2024, 11:55 AM |
Shafer Christina | CHIEF COMMERCIAL OFFICER | Feb 20, 2024 | Sale | $9.56 | 2,153 | 20,583 | 60,308 | Feb 22, 2024, 04:05 PM |
Hulihan Joseph | CHIEF MEDICAL OFFICER | Feb 16, 2024 | Sale | $9.98 | 2,814 | 28,084 | 66,635 | Feb 21, 2024, 04:06 PM |
Braunstein Scott | CHAIRMAN AND CEO | Feb 16, 2024 | Sale | $9.94 | 11,850 | 117,789 | 223,512 | Feb 21, 2024, 04:05 PM |
Shafer Christina | CHIEF COMMERCIAL OFFICER | Aug 08, 2023 | Sale | $8.93 | 11 | 98 | 40,626 | Aug 08, 2023, 09:05 PM |
Shafer Christina | CHIEF COMMERCIAL OFFICER | Aug 07, 2023 | Sale | $9.52 | 2,385 | 22,705 | 40,637 | Aug 08, 2023, 09:05 PM |
Braunstein Scott | CHAIRMAN AND CEO | Aug 07, 2023 | Sale | $9.55 | 6,413 | 61,244 | 160,792 | Aug 08, 2023, 09:05 PM |
Braunstein Scott | CHAIRMAN AND CEO | Aug 08, 2023 | Sale | $8.94 | 30 | 268 | 160,762 | Aug 08, 2023, 09:05 PM |
Pfanstiel Steven | CFO AND COO | Aug 08, 2023 | Sale | $8.93 | 14 | 125 | 49,324 | Aug 08, 2023, 09:05 PM |
Pfanstiel Steven | CFO AND COO | Aug 07, 2023 | Sale | $9.54 | 2,790 | 26,617 | 49,338 | Aug 08, 2023, 09:05 PM |
MANNING MARTHA E | SVP, GEN. COUNSEL & CORP. SEC. | Aug 08, 2023 | Sale | $8.93 | 11 | 98 | 33,025 | Aug 08, 2023, 09:05 PM |
MANNING MARTHA E | SVP, GEN. COUNSEL & CORP. SEC. | Aug 07, 2023 | Sale | $9.54 | 2,169 | 20,692 | 33,036 | Aug 08, 2023, 09:05 PM |
Hulihan Joseph | CHIEF MEDICAL OFFICER | Aug 08, 2023 | Sale | $8.93 | 13 | 116 | 47,614 | Aug 08, 2023, 09:05 PM |
Hulihan Joseph | CHIEF MEDICAL OFFICER | Aug 07, 2023 | Sale | $9.55 | 2,889 | 27,590 | 47,627 | Aug 08, 2023, 09:05 PM |
Fischer Seth H. Z. | Director | Feb 06, 2023 | Sale | $6.54 | 1,018 | 6,658 | 6,026 | Feb 08, 2023, 04:37 PM |
Ezickson Elan | Director | Feb 06, 2023 | Sale | $6.56 | 750 | 4,920 | 5,600 | Feb 08, 2023, 04:36 PM |
Austin Charles | Director | Feb 06, 2023 | Sale | $6.49 | 1,073 | 6,964 | 5,277 | Feb 08, 2023, 04:36 PM |
Shafer Christina | Chief Commercial Officer | Nov 09, 2022 | Option Exercise | $4.70 | 1,505 | 7,073 | 25,647 | Nov 14, 2022, 07:43 AM |
VITULLO NICOLE | Director | Mar 15, 2021 | Sale | $15.87 | 4,250 | 67,447 | 0 | Mar 16, 2021, 04:58 PM |
Smith Edward F | Former VP, CFO & Treasurer | Mar 09, 2021 | Option Exercise | $4.16 | 35,927 | 149,456 | 53,644 | Mar 11, 2021, 04:04 PM |
Smith Edward F | Former VP, CFO & Treasurer | Mar 09, 2021 | Sale | $17.80 | 40,356 | 718,337 | 13,288 | Mar 11, 2021, 04:04 PM |
Smith Edward F | CFO | Jan 30, 2020 | Sale | $2.05 | 2,380 | 4,879 | 17,717 | Feb 03, 2020, 06:29 PM |
Braunstein Scott | Chief Executive Officer | Dec 13, 2019 | Buy | $1.25 | 100,000 | 125,000 | 100,000 | Dec 13, 2019, 04:08 PM |
Smith Edward F | CFO | May 16, 2019 | Sale | $5.03 | 24,211 | 121,781 | 20,097 | May 20, 2019, 04:20 PM |
Cashman Christopher Michael | CEO | Mar 18, 2019 | Option Exercise | $1.04 | 31,662 | 32,928 | 271,423 | Mar 20, 2019, 05:57 PM |
Cashman Christopher Michael | CEO | Jan 28, 2019 | Sale | $3.13 | 8,142 | 25,484 | 239,761 | Jan 30, 2019, 04:09 PM |
Smith Edward F | CFO | Jan 29, 2019 | Sale | $3.06 | 2,492 | 7,626 | 44,308 | Jan 30, 2019, 04:08 PM |
Smith Edward F | CFO | Jan 29, 2018 | Sale | $7.91 | 3,000 | 23,730 | 49,800 | Jan 29, 2018, 08:00 PM |
Cashman Christopher Michael | CEO | Jan 18, 2018 | Sale | $6.28 | 9,566 | 60,074 | 247,903 | Jan 22, 2018, 08:41 PM |
Bain Capital Life Sciences Investors, LLC | 10% Owner | Dec 19, 2017 | Sale | $7.43 | 150,000 | 1,114,670 | 4,032,682 | Dec 19, 2017, 08:30 PM |
Bain Capital Life Sciences Investors, LLC | 10% Owner | Dec 18, 2017 | Sale | $7.50 | 300,000 | 2,251,440 | 4,127,453 | Dec 19, 2017, 08:30 PM |
Bain Capital Life Sciences Investors, LLC | 10% Owner | Dec 15, 2017 | Sale | $8.10 | 822,547 | 6,658,691 | 4,530,335 | Dec 19, 2017, 08:30 PM |
Mehra Anand | 10% Owner | Oct 20, 2016 | Sale | $1.39 | 750,683 | 1,042,699 | 1,134,851 | Oct 24, 2016, 04:49 PM |
Canaan VII LP | 10% Owner | Aug 08, 2016 | Sale | $1.50 | 19,950 | 29,925 | 1,850,783 | Aug 09, 2016, 10:03 AM |
Canaan VII LP | 10% Owner | Aug 05, 2016 | Sale | $1.50 | 129,204 | 193,806 | 1,870,733 | Aug 09, 2016, 10:03 AM |
Canaan VII LP | 10% Owner | Aug 04, 2016 | Sale | $1.50 | 3,329 | 4,994 | 1,999,937 | Aug 05, 2016, 10:18 AM |
Canaan VII LP | 10% Owner | Aug 03, 2016 | Sale | $1.50 | 142,254 | 213,381 | 2,003,266 | Aug 05, 2016, 10:18 AM |
Canaan VII LP | 10% Owner | Jul 29, 2016 | Sale | $1.71 | 24,540 | 41,963 | 2,145,520 | Aug 02, 2016, 12:22 PM |
Canaan VII LP | 10% Owner | Jul 27, 2016 | Sale | $1.80 | 209 | 376 | 2,170,060 | Jul 27, 2016, 04:30 PM |
Canaan VII LP | 10% Owner | Jul 26, 2016 | Sale | $1.81 | 20,380 | 36,888 | 2,170,269 | Jul 27, 2016, 04:30 PM |
Canaan VII LP | 10% Owner | Jul 25, 2016 | Sale | $1.86 | 137,617 | 255,968 | 2,190,649 | Jul 26, 2016, 10:08 AM |
Canaan VII LP | 10% Owner | Jul 22, 2016 | Sale | $1.94 | 133,133 | 258,278 | 2,328,266 | Jul 26, 2016, 10:08 AM |
Cashman Christopher Michael | President and CEO | Feb 09, 2016 | Option Exercise | $1.04 | 24,684 | 25,671 | 140,769 | Feb 11, 2016, 05:17 PM |
Cashman Christopher Michael | President and CEO | Nov 06, 2015 | Buy | $5.61 | 3,561 | 19,977 | 116,085 | Feb 11, 2016, 05:17 PM |
Bloch Stephen M | Director | Sep 28, 2015 | Option Exercise | $1.04 | 39,550 | 41,132 | 39,550 | Feb 04, 2016, 06:48 PM |
Bloch Stephen M | Director | Sep 28, 2015 | Option Exercise | $1.04 | 39,550 | 41,132 | 39,550 | Sep 28, 2015, 08:12 PM |
MAYLEBEN TIMOTHY M | Director | Jul 16, 2015 | Option Exercise | $1.04 | 42,550 | 44,252 | 42,550 | Jul 17, 2015, 04:01 PM |
Cashman Christopher Michael | President and CEO | Jul 01, 2015 | Option Exercise | $1.04 | 14,086 | 14,649 | 112,524 | Jul 02, 2015, 04:08 PM |
Bloch Stephen M | Director | Jun 10, 2015 | Option Exercise | $1.04 | 3,000 | 3,120 | 3,000 | Jun 11, 2015, 05:26 PM |
Farfel Gail M | Chief Clinical Dev & Reg Offic | Apr 21, 2015 | Option Exercise | $1.04 | 30,000 | 31,200 | 30,000 | Apr 23, 2015, 04:48 PM |
Farfel Gail M | Chief Clinical Dev & Reg Offic | Apr 21, 2015 | Sale | $9.48 | 30,000 | 284,511 | 0 | Apr 23, 2015, 04:48 PM |
Cashman Christopher Michael | PRESIDENT AND CEO | Mar 06, 2015 | Option Exercise | $1.04 | 17,608 | 18,312 | 98,438 | Mar 10, 2015, 01:16 PM |
Cashman Christopher Michael | PRESIDENT AND CEO | Oct 08, 2014 | Option Exercise | $1.04 | 80,830 | 84,063 | 80,830 | Oct 09, 2014, 04:05 PM |
Domain Partners VI, L.P. | 10% Owner | Aug 05, 2014 | Buy | $8.00 | 419,744 | 3,357,952 | 2,476,886 | Aug 07, 2014, 03:06 PM |
Mehra Anand | Director | Aug 05, 2014 | Buy | $8.00 | 750,683 | 6,005,464 | 1,859,639 | Aug 07, 2014, 12:43 PM |
Canaan VII L P | Director | Aug 05, 2014 | Buy | $8.00 | 625,000 | 5,000,000 | 2,461,398 | Aug 06, 2014, 09:03 AM |
Bloch Stephen M | Director | Aug 05, 2014 | Buy | $8.00 | 625,000 | 5,000,000 | 2,461,398 | Aug 06, 2014, 09:03 AM |
Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
---|---|---|---|---|
SUVRETTA CAPITAL MANAGEMENT, LLC | 5,346,119 | 2.63% | 2.71% | Growth At A Reasonable Price |
BLACKROCK INC. | 4,599,278 | 0.00127% | 10.94% | Other |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,581,250 | 0.06% | -11.13% | Other |
GEODE CAPITAL MANAGEMENT, LLC | 1,139,494 | 0.0013% | 9.05% | Other |
D. E. SHAW & CO., INC. | 50,000 (Call) | 0.00042% | Exited | Other |
AQR CAPITAL MANAGEMENT LLC | 23,024 | 0.00047% | New | Other |
BALYASNY ASSET MANAGEMENT L.P. | 15,873 | 0.00026% | Exited | Event Driven |
D. E. SHAW & CO., INC. | 11,400 | 0.0001% | Exited | Other |
Period of Report: 12/31/2023
10-K/10-Q Filings: View